Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...

Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...

Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE ...

Fast-track status will allow Solid Biosciences to have more frequent meetings with the FDA throughout the treatment-development process and, potentially, get the product to patients faster than would ...

Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia: Bala Cynwyd, Pennsylvania Saturday, January 25, 2025, 15: ...

Charlestown, Massachusetts Thursday, January 23, 2025, 15:00 Hrs [IST] ...

Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose ; Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will b ...

Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion ...